MDA is committed to transforming the lives of people affected by muscular dystrophy, ALS, and related neuromuscular diseases. Please see the resources below for a sampling of statements and communications to policymakers on a number of issues that affect the neuromuscular community. For any questions on these communications or other MDA public priorities, please refer to www.MDA.org/advocacy or email advocacy@mdausa.org.

2025

• Coalition Comments to Congressional Leadership in Support of National Institutes of Health (6.10.2025)
• Coalition Comments on Confirmation of Frank Bisignano as Social Security Commissioner (6.6.2025)
• Coalition Comments on House-Passed Big Beautiful Bill Act (6.6.2025)
• Coalition Comments to Congressional Appropriations Leaders in Support of National Institutes of Health (6.5.2025)
• Coalition Comments Expressing Concerns on One Big Beautiful Bill Act (6.5.2025)
• Letter to Chair and Ranking Member of the House and Senate Appropriations Subcommittees on Labor, Health, Human Services and Education on FY26 Newborn Screening Program Appropriations (5.23.2025)
  • House Appropriations
  • Senate Appropriations
• Coalition Comments to Congressional Leadership on Support for NIH and Brain Health (5.23.2025)
• Coalition Comments to House of Representatives Leadership on ACA Marketplace Concerns in Reconciliation (5.21.2025)
• MDA Comments on One Big Beautiful Bill Act (5.20.25)
• Coalition Comments to House and Senate Education Appropriations Leaders on Technical Assistance Centers (5.20.2025)
• Coalition Comments to House Appropriations Leaders on Biomedical Research (5.14.2025)
• Amicus Brief in Alliance of Health Care Sharing Ministries v. Colorado Division of Insurance in the 10th Circuit (5.14.2025)
• Coalition Comments to House Agriculture Committee on SNAP Program Cuts (5.13.2025)
• MDA Comments to House Energy and Commerce Committee on Budget Reconciliation Package (5.12.2025)
• Coalition Comments on Cuts to Medicaid in Budget Reconciliation Package and ACA Marketplace Weakening (5.12.2025)
• Coalition Comments to Social Security Administration on Security Authentication PIN Emergency Request (5.9.2025)
• Coalition Comments to House and Senate Appropriations Leaders on NIAMS FY26 Appropriations (5.8.2025)
• Coalition Comments to DOT re: Ensuring Lawful Regulation; Reducing Regulation and Controlling Regulatory Costs RFI (5.5.2025)
• Coalition Comments to HHS Secretary Kennedy on Elimination of Advisory Committee on Heritable Disorders in Newborns and Children (5.5.2025)
• Coalition Comments to Department of Housing and Urban Development on Fair Housing Revisions Interim Final Rule (5.2.2025)
• Coalition Comments to Congressional Appropriators on FY26 Appropriations for Critical Housing Programs for Adults with Disabilities (4.30.2025)
• Coalition Comments to House Energy and Commerce Committee Urging Against Medicaid Cuts (4.28.2025)
• Coalition Comments to House and Senate Appropriators to Reject Proposed Cuts to HHS (4.25.2025)
• Coalition Comments to Congressional Appropriations Leaders on Administration’s Draft Fiscal Year 2026 Budget for the Department of Health and Human Services (4.25.2025)
• Coalition Comments on Introduction of IDEA Full Funding Act (4.24.2025)
• Coalition Comments to Congressional Appropriations Leads on FY26 Education Appropriations (4.21.2025)
• Coalition Comments in Support of Adding Duchenne Muscular Dystrophy (DMD) to Indiana's Newborn Screening Panel (4.18.2025)
• Coalition Comments in Support of the HCBS Settings Rule (4.18.2025)
• Coalition Comments in Response to the U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) for the Marketplace Integrity and Affordability Proposed Rule (4.11.2025)
• MDA Comments in Response to the U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) for the Marketplace Integrity and Affordability Proposed Rule (4.11.2025)
• MDA Comments in Support of the IDEA Full Funding Act (4.11.2025)
• Coalition Comments in Support of Mobility Means Freedom Tax Credit Act (4.10.25)
• Coalition Comments in Support of the CONNECT for Health Act (4.3.2025)
• Coalition Comments in Support of FY 2026 NIH Appropriations from Ad Hoc Group for Medical Research (4.7.2025)
• Coalition Comments in Support of the Accelerating Kids' Access to Care Act (3.26.2025)
• Coalition Comments in Response to Ongoing Developments at the Social Security Administration (SSA) (3.20.2025)
• Coalition Comments Requesting Fiscal Year 2026 Appropriations for ALS Programs (3.18.2025)
• Coalition Comments in Support of Preserving Patient Access to Home Infusion Act (3.13.2025)
  • House Comments
  • Senate Comments
• MDA Comments in Response to NIH Strategic Plan Request for Comment (3.12.2025)
• MDA Comments Opposing Funding Cuts in Recently Introduced Continuing Resolution (3.11.2025)
• Coalition Comments in Support of the SSI Savings Penalty Elimination Act (3.10.2025)
• Coalition Comments on U.S. Department of Health and Human Services Removal of Notice and Comment Opportunities (3.6.2025)
• Coalition Comments on Legislative Efforts to Undermine the Regulatory Process and Weaken Public Health Protections (3.4.2025)
• MDA Comments on U.S. House Adoption of Budget Resolution (2.26.2025)
• Coalition Comments on Pharmacy Benefit Manager (PBM) Reform Patient Priorities (2.25.2025)
• Coalition Comments to Secretary of Transportation Duffy on the Air Travel Experience for Disabled Veterans and Passengers with Disabilities (2.25.2025)
• Coalition Comments to Congressional Leadership on Securing Access to Telehealth Services (2.24.2025)
• Neuromuscular Advocacy Collaborative (NMAC) Comments on National Institutes of Health (NIH) Indirect Costs Cap (2.13.2025)
• MDA Comments on Airline Passenger Rights Notice of Proposed Rulemaking (NPRM) (2.10.2025)
• MDA Comments on Nondiscrimination on the Basis of Disability Air Travel Information Collection Advanced NPRM (2.10.2025)
• Coalition Comments on U.S. Secretary of Education Nominee Linda McMahon (2.6.2025)
• Coalition Comments on Wheelchair Repairs and Maintenance Policy Recommendations (2.5.2025)
• Coalition Comments in Support of Pharmacy Benefit Manager (PBM) Reform (2.5.2025)
• Coalition Comments on Trump Administration Defending No-Cost Preventive Care in Braidwood Case (1.30.2025)
• Coalition Comments on Wheelchair Repair Solutions and Principles (1.29.2025)
• Coalition Comments to President Trump on Rare Disease Community Priorities (1.24.2025)
• Amicus Brief Filed in Kansas v. U.S. (1.24.2025)
• Summary of Major Provisions in DOT Final Rule for Wheelchair Users (1.21.2025)
• Amicus Brief Filed in Response to Challenges to Section 1557 of the Affordable Care Act (ACA) Final Rule from U.S. Department of Health and Human Services (1.9.2025)

2024

• MDA Comments to Senate Health, Education, Labor, and Pensions (HELP) and Senate Finance Committee Leadership on End-of-Year Neuromuscular Community Priorities in Continuing Resolution (12.20.24)
• Coalition Comments to Congressional Leadership on Potential Changes to Medicaid (12.19.24)
• MDA Comments to Speaker Johnson on End-of-Year Neuromuscular Community Priorities in Continuing Resolution (12.19.24)
• Amicus Brief in American Association of Ancillary Benefits v. Becerra (12.18.24)
• MDA Comments to House Committee on Energy and Commerce Leadership on Neuromuscular Community Priorities in End-of-Year Package (12.18.24)
• Coalition Comments to Centers for Medicare and Medicaid Services on Long-Term Care (LTC) Pharmacies (12.17.24)
• Coalition Comments to Centers for Medicare and Medicaid Services on Federal Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) Program (12.16.24)
• Coalition Comments from NMAC Members to Congressional Leadership in Support of the Accelerating Kids' Access to Care Act in End-of-Year Package Negotiations (12.12.24)
• Coalition Comments to Congressional Leadership on Partnership to Protect Coverage Healthcare Priorities (12.10.24)
• Coalition Comments to House Budget Committee and Senate Budget Committee Leadership on Protection of and Potential Cuts to Medicaid (12.10.24)
• Amicus Briefs Filed in Response to Challenges to Section 1557 of the Affordable Care Act (ACA) Final Rule from U.S. Department of Health and Human Services:
  • Texas v. Becerra (12.4.24)
  • Tennessee v. Becerra (11.26.24)
• Coalition Comments to Congressional Leadership on Rare Pediatric Disease Priority Review Voucher Program Reauthorization (12.4.24)
• Coalition Comments to Congressional Leadership on Diagnostic Medical Equipment (DME) Access (12.2.24)
• Coalition Comments to President Biden Urging Finalization of Ensuring Safe Accommodations for Air Travelers with Disabilities Using Wheelchairs Rule (11.26.2024)
• Coalition Comments on Access to Assistive Technology, Auxiliary Aids, Services, and Accommodations & Use of Assistive Technology in PreK-16 Schools (11.13.24)
• Coalition Comments to HHS on Notice of Benefit and Payment Parameters for 2026 (11.12.24)
• Coalition Comments in Response to Proposed Data Collection on Proprietary Guidelines and Medicare Advantage Plan Audit Protocol (11.12.24)
• Coalition Comments to Support S.5070, the Ensuring Access to Medicaid Buy-In Programs Act (11.12.24)
• Coalition Comments on Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2026; Basic Health Program (11.12.24)
• Coalition Comments on Access to Assistive Technology, Auxiliary Aids, Services, and Accommodations (11.6.24)
• Coalition Comments to UnitedHealthcare on Changes to Prior Authorization Policies for Outpatient Rehabilitation Therapy Services (10.22.24)
• MDA Comments to Federal Emergency Management Agency (FEMA) on Proposed Rule to Update FEMA Public Assistance Regulations (10.18.24)
• Coalition Comments to Centers for Medicare & Medicaid Services (CMS) on Service Level Data Collection for Medicare Advantage Plans (10.8.24)
• Amici Curiae Brief to U.S. District Court in Deferred Action for Childhood Arrivals Case, Kansas et al. v. U.S. (10.2.24)
• MDA Testimony to FDA in Response to Diversity Action Plan Guidance (9.26.24)
• MDA Comments in Advance of Senate Health, Education, Labor, and Pensions (HELP) Committee Markup of Health Bills (9.26.24)
• MDA Testimony in front of FDA CBER Patient Listening Session (9.20.2024)
• Coalition Comments in Support of the Think Differently Database Act (9.17.24)
• Coalition Comments Asking House Leadership to Support Passage of Priority Review Voucher Reauthorization (9.16.24)
• Coalition Comments Asking Senate Leadership to Support Passage of Priority Review Voucher Reauthorization (9.16.24)
• Coalition Comments to the Department of Transportation Urging Finalization of the Wheelchair User Experience Rule (9.13.24)
• Coalition Comments to the Contract Year 2025 Medicare Physician Fee Schedule Proposed Rule (9.9.24)
• MDA Comments on FDA Platform Technology Designation Program for Drug Development Guidance for Industry (8.28.24)
• MDA Comments to Consumer Financial Protection Bureau on Proposed Medical Debt Rule (8.12.24)
• Coalition Comments to Consumer Financial Protection Bureau on Proposed Medical Debt Rule (8.12.24)
• MDA Testimony to the Advisory Committee on Heritable Disorders in Newborns & Children on Duchenne Muscular Dystrophy Nomination (8.9.24)
• Coalition Comments to Social Security Administration on Process to Authorize Information Collection for Claims (8.8.24)
• Coalition Comments to U.S. Department of Transportation Re: Request For Information on Opportunities and Challenges of AI in Transportation (8.1.24)
• MDA Comments to U.S. Senators Bob Casey (D-PA) and Eric Schmitt (R-MO) on the ENABLE Act (7.29.24)
• MDA Comments to Election Assistance Commission Form Filler Tool (07.22.24)
• Coalition Comments on the ALS Better Care Act from physicians who provide multidisciplinary care to people living with ALS (7.10.24)
• Coalition Comments on Pending National Coverage Analysis for Standing Systems in Power Wheelchairs (6.28.24)
• Coalition Comments on Supporting Non-Defense Discretionary Federal Funding in FY25 (6.25.24)
• Coalition Comments on Rare Disease Pediatric Priority Review Voucher (PRV) Reauthorization (6.24.24)
• Coalition Comments on DOT NPRM (6.12.24)
• MDA Comments on DOT NPRM (6.12.24)
• MDA Comments on House Energy and Commerce Committee Full Committee Markup on Health Bills (6.11.24)
• Coalition Comments on 2026 Notice of Benefit and Payment Parameters (6.7.24)
• Coalition Comments to DOJ on Accessible Voting (5.30.24)
• Coalition Comments to CMS in Response to RFI on Medicare Advantage Data (5.29.24)
• Coalition Comments on SNAP in House Farm Bill Reauthorization (5.23.24)
• MDA Comments on House Energy and Commerce Committee Health Legislation Markup (5.16.24)
• Coalition Comments on FY25 Education Appropriations (5.10.24)
• MDA Comments to ACHDNC on DMD Nomination (5.9.24)
• Senate Comments to Senate Appropriations Committee on Newborn Screening Appropriations (5.7.24)
• Coalition Comments on FY25 Education Appropriations Asks (5.7.24)
• Coalition Comments on 2024 FAA Reauthorization - PVA (5.6.24)
• Coalition Comments on 2024 FAA Reauthorization - NMAC (5.3.24)
• MDA Comments on Medicaid Access Hearing in House Energy and Commerce Committee (4.30.24)
• Coalition Comments on MAXRX MPPP Model Documents (4.29.24)
• Coalition Comments on DOT NPRM for Wheelchair Travel Comment Extension (4.26.24)
• Coalition Comments on HHS Final Rule Section 1557 (4.26.24)
• Coalition Comments on NCATS FY 25 Funding (4.17.24)
• MDA Comments on House Energy & Commerce Telehealth Hearing (4.9.24)
• Coalition Comments on DOJ Complaint Data Reports (3.28.24)
• Coalition Comments on MAPRx Part D Redesign Guidance, Part 2 (3.15.24)
• MDA Comments on ERISA RFI (3.15.24)
• Coalition Comments on Restore Protections for Dialysis Patients Act (3.7.24)
• Coalition Comments on ALS Community FY25 Funding Priorities (3.5.24)
• Coalition Comments on MAPRx Part D Redesign Guidance (3.1.24)
• Coalition Comments on BENEFIT Act (2.29.24)
• MDA Statement to House Committee on Energy and Commerce on Rare Disease Day Hearing (2.29.24)
• Coalition Comments on Final FAA Reauthorization Act Recommendations for Passengers with Disabilities (2.21.24)
• Coalition Comments on Telehealth Policies (2.22.24)
• Coalition Comments on Florida Children’s Health Insurance Program Eligibility Extension (2.21.24)
• Coalition Comments on Proposed Rescission of Association Health Plan Final Rule (2.20.24)
• Coalition Comments on Ensuring Medicaid Continuity for Children in Foster Care Act of 2023/S. 3196 (2.16.24)
• MDA Comments on DOJ Proposed Rule on Accessible MDE (2.12.24)
• Coalition Comments in Response to DOJ Proposed Rule on Accessible MDE (2.12.24)
• Coalition Comments on Medicaid Unwinding IFR (2.2.24)
• MDA Comments in Response to Senate HELP and Sen. Cassidy RFI on Gene and Cell Therapies (1.31.24)
• Amicus Brief in U.S. Food and Drug Administration v. Alliance for Hippocratic Medicine (1.31.24)
• MDA Comments to ACHDNC on DMD Nomination Updates (1.29.24)
• Coalition Comments on FY24 Newborn Screening Appropriations (1.17.24)
• Coalition Comments on Loper Supreme Court Oral Arguments (1.17.24)
• Coalition Comments on HHS Notice of 2025 Benefit and Payment Parameters (1.9.24)
• Coalition Comments on CMS Proposed Rule on Medicare Advantage and Medicare Part D (1.5.24)

2023

• Coalition Comments on Proposed Rule to Strengthen Consumer Protections in Association Health Plans (12.19.23)
• Coalition Comments on Ensuring Patient Access to Critical Breakthrough Products Act (12.12.23)
• MDA Comments on FDA Proposed Rule on Lab-Developed Tests (12.4.23)
• Rare Disease Patient Group Letter to Congress on Inflation Reduction Act (12.1.23)
• MDA Comments to FDA on Individualized Cell and Gene Therapies (11.20.23)
• Amicus Brief in US v. Florida-Olmstead (11.15.23)
• MDA Comments to HHS on Section 504 Proposed Updates (11.13.23)
• Coalition Comments to HHS on Section 504 Proposed Updates (11.13.23)
• MDA Comments to ACHDNC on DMD Nomination (11.2.23)
• Amicus Brief in Texas v. Mayorkas (10.27.23)
• Coalition Comments to President Biden on DACA ACA Rule (10.16.23)
• Coalition Comments to CMS on Medicare Unwinding (10.11.23)
• Coalition Comments to House Ways and Means Committee on No Surprises Act (10.3.23)
• Coalition Comments to DOJ on Proposed Rule on Web Accessibility (10.3.23)
• Amicus Brief in Loper v. Raimondo (9.23.23)
• MDA Comments to FDA Cell and Gene Therapies Advisory Committee (09.20.23)
• Coalition Comments to CMS on Medicare Prescription Payment Plan Guidance (09.20.23)
• Coalition Letter to Treasury, CFPB, and DHHS on Medical Debt RFI (09.11.23)
• Coalition Letter to Treasury, DOL, and DHHS on Short-Term, Limited Duration Insurance (09.11.23)
• Letter to HHS on Disability Designation Decision (09.06.2023)
• Coalition Comments to CMS on Emerging Technologies (08.28.2023)
• Coalition Statement on Medicaid Unwinding (08.21.2023)
• MDA Comments on Proposed CMS National Coverage Analysis Evidence Reviews (08.21.2023)
• NAIMS Letter to Rep. Kelly on HR 3503 (08.16.2023)
• MDA Testimony to ACHDNC on the DMD Nomination (08.10.2023)
• Acheson Hotel v. Laufer Amicus Brief (08.09.2023)
• Haller v HHS Amicus Brief (08.08.2023)
• MDA Comments to FDA on Decentralized Clinical Trials (08.01.2023)
• Coalition Comments to US Department of Education on IDEA Part B (08.01.2023)
• Coalition Statement on Medicaid Unwinding Data (07.28.2023)
• Coalition Letter to the Senate Finance Committee on PBM Reform (07.26.2023)
• Letter to HELP Leadership on Pandemic and All-Hazards Preparedness Act (07.20.2023)
• Coalition Letter to House Leaders Supporting House FAA Reauthorization Bill (7.17.2023)
• Coalition Letter to House Leaders Supporting the Protecting Healthcare for All Patients Act (07.13.2023)
• Coalition Letter on Telehealth Excepted Benefit (07.12.2023)
• Coalition Letter to White House on Medicaid Unwinding (07.10.2023)
• Coalition Statement on Short-Term Plans Rule (07.07.2023)
• Coalition Comments to HHS on Medicaid Access Rule (06.29.2023)
• Coalition Comments to HHS on Medicaid Managed Care Rule (06.29.2023)
• Coalition Letter Supporting Intermittent Catheter Coding Reform (06.26.2023)
• Coalition Letter to Congressional Leaders Supporting the Medicare Orthotics & Prosthetics Patient-Centered Care Act (06.23.2023)
• Coalition Letter to HHS on DACA and ACA Plans (06.23.2023)
• Coalition Letter to House Leaders on Telehealth Benefit Expansion for Workers Act (06.21.2023)
• Coalition Letter to House Leaders on Junk Plans (06.21.2023)
• Coalition Comments to US Dept of Education (06.12.2023)
• MDA Letter to Leadership on American Aviation Act of 2023 (06.12.2023)
• Coalition Letter on Medicare Part D Redesign (06.06.2023)
• Coalition Letter to Committee on Healthcare Affordability Markup (06.06.2023)
• Coalition Letter Opposing the More Teaching Less Testing Act (06.06.2023)
• Coalition Letter to CMS on Medicaid Unwinding (05.30.2023)
• Coalition Letter to CMS on Seat Elevation Systems (05.19.2023)
• MDA Statement at FDA Cell and Gene therapy Adcomm on SRP9001 (5.12.2023)
• Group Letter to Congress on PBMs (05.10.2023)
• MDA Comments for FDA Cell and Gene Therapy Adcomm (05.05.2023)
• MDA Testimony  for the ACHDNC on the DMD Nomination (05.04.2023)
• MDA Comments to FDA on External Controls (05.02.2023)
• Coalition Letter Supporting RARE Act (05.01.2023)
• Amicus Brief-Alliance for Hippocratic Medicine v. FDA (05.01.2023)
• ALS Group Letter to Congress on ALS Funding Priorities (04.28.2023)
• Coalition Comments to HHS of Section 504 (04.26.2023)
• Coalition Comments on Medicaid Cuts (04.24.2023)
• Coalition Letter on Medicaid Cuts (04.20.2023)
• CCD Coalition Letter to Congress on Education Funding (04.19.2023)
• NCATS Alliance Letter to Congress on Budget (04.18.2023)
• NORD Coalition Comments to CMS on Medicare Drug Pricing Negotiation (04.14.2023)
• MDA Comments to CMS on Medicare Drug Pricing Negotiation (04.14.2023)
• Coalition Letter to Social Security Administration on Food & ISM (04.14.2023)
• Group Statement on Texas Hippocratic Medicine Ruling (04.11.2023)
• Coalition Statement on Braidwood v Becerra (03.30.2023)
• Coalition Letter to Congress on SSA Funding (03.28.2023)
• Coalition Medicaid Letter to the White House and Congress (03.23.2023)
• Coalition Statement on Ways and Means Hearing on Why Health Care is Unaffordable (03.23.2023)
• MDA Statement to FDA Neurological Adcomm on Tofersen (03.22.2023)
• Coalition Letter Opposing the REINS Act (03.17.2023)
• MDA Comments to CMS on Seat Elevation Systems (03.17.2023)
• Health Care Coalition Comments to CMS on Prior Reauthorization Rule (03.13.2023)
• Rehabilitation Coalition Comments to CMS on Prior Reauthorization Rule (03.13.2023)
• MDA Statement on Access to FDA Approved Therapies (03.08.2023)
• Coalition NIAMS Funding Letter (03.03.2023)
• MDA Letter to Senate Commerce Committee on FAA Reauthorization (2.24.2023)
• Coalition Comments to CMS on Medicare Advantage Rule (02.13.2023)
• MDA Statement on Negative ACHDNC Duchenne Vote (02.10.2023)
• MDA Testimony in front of the ACHDNC on the DMD Nomination (02.10.2023)
• Group Letter to CMS on Low Income Subsidies (02.07.2023)
• Letter Supporting the Protecting Healthcare for All Patients Act (1.31.2023)
• Coalition Comments to HHS on Benefit and Payment Parameters (01.30.2023)
• Coalition Comments to HHS on Essential Health Benefits (1.30.2023)

2022

• Group LGMD Comments on Gene Therapy PFDD (12.13.2022)
• Coalition Comments to HHS on National Provider Directory (12.06.2022)
• Coalition Letters to U.S. House and Senate Supporting Medicare Orthotic & Prosthetic Patient-Centered Care Act (12.06.2022)
• Group Letter to Congress on FDA - Clinical Trial Reforms (12.06.2022)
• Group Letter to Congress on FY 23 NCATS Appropriations (12.01.2022)
• Coalition Letter on Surprise Medical Billing Implementation (11.15.2022)
• Group Letter to Congressional Leaders on Follow-Up to FDA User Fees Legislation (11.14.2022)
• Letter to HHS Secretary on DACA and Health Programs (11.14.2022)
• Letter to Congressional Leadership on SSI and ABLE Act Bill (11.10.2022)
• Coalition Letter about 2023 Educational Funding to Congressional Leaders (11.07.2022)
• Coalition Comments on Medicaid (11.04.2022)
• Coalition Comments on CMS RFI on Equity (11.04.2022)
• Coalition Letter about 2023 SSA Funding to Congressional Leaders (11.03.2022)
• Medicare Guide with MAPRx (11.01.2022)
• Home Infusion Stakeholder Sign-On Letter (10.31.2022)
• Coalition COVID IFR Comments (10.27.2022)
• Coalition Family Glitch Statement (10.11.2022)
• ITEM Coalition Comments on Section 1557 Proposed Rule (10.03.2022)
• Consortium for Constituents with Disabilities 1557 Comments (10.03.2022)
• Health Partners Comments on Section 1557 (10.3.2022)
• Rehabilitation Coalition Comments on Section 1557 (10.3.2022)
• Accelerating Kids Access to Care Act Support Letter (10.3.2022)
• Comments to CMS on Standing Wheelchairs (9.14.2022)
• Telehealth Priorities Coalition Letter (9.13.2022)
• NBPP Priorities Coalition Letter (9.13.2022)
• Coalition Comments on Title IX (9.12.2022)
• Support Letter for Accelerating Kids' Access to Care Act (9.8.2022)
• Coalition Comments on Kelly v. Becerra (9.7.2022)
• Coalition Comments on 2023 Proposed PFS Rule (9.6.2022)
• MDA Comments to Advisory Committee on AMX0035 (8.23.2022)
• Coalition Inflation Reduction Act Statement (8.12.2022)
• Coalition Comments on Student Loan Rule (8.11.2022)
• Coalition Letter on Inflation Reduction Act (08.5.2022)
• Coalition Letter to Senate Leaders on Reconciliation Bill (8.4.2022)
• Patient Group User Fee Authorization Letter (8.1.2022)
• Coalition Statement on Kelley v. Becerra (07.22.2022)
• VALID Act Support Letter (07.20.2022)
• LGMD Community Announces LGMD ICD10 Codes (6.29.2022)
• Coalition CMS Letter on HCPCS Coding Reform (6.28.2022)
• MDA Letter to Sen. Crapo and Wyden on ABLE Age Act (6.21.2022)
• LGMD Community Comments on Final LGMD Codes (6.17.2022)
• Coalition Comments on Family Glitch Fix (6.6.2022)
• Coalition Letter on RARE Act (6.3.2002)
• MDA Letter to Senate Commerce Leaders on FAA Reauthorization (6.1.2022)
• MDA Comments to ATBCB on Diagnostic Equipment Standards (5.27.2022)
• MDA DOT Comments on Single-Aisle Aircraft Lavatories (05.25.2022)
• Coalition Letter on SSI Savings Penalty Elimination Act (05.24.2022)
• Coalition Coverage Priorities in Reconciliation (05.20.2022)
• Pompe Disease PFDD Voice of the Patient Report (05.19.2022)
• Final ACAA Advisory Committee Report (5.16.2022)
• Coalition Letter Supporting Consumer Assistance Programs (05.04.2022)
• CCD Coalition Letter to HHS on Section 504 of the Rehabilitation Act (4.26.2022)
• CCD Comments on Public Charge (04.25.2022)
• Coalition Comments to HHS on Public Charge (4.25.2022)
• MDA Follow-up Comments to DOT on Wheelchair Users and Airplanes (04.25.2022)
• CCD Coalition Appropriations Request (04.25.2022)
• Coalition Document to CMS on Medicaid Access (04.18.2022)
• Coalition Letter to Congress on Mental Health Recommendations (4.7.2022)
• Coalition Letter to HHS on VALID Act (04.05.2022)
• Patient Letter to Congress and HHS on Accelerate Approval (04.04.2022)
• Coalition Letter to Congress on Paid Leave (04.01.2022)
• MDA Statement to FDA Neurological Advisory Committee on AMX0035 (03.30.2022)
• CCD Coalition Letter to US House and US Senate on ACAAA Support (3.23.2022)
• Letter to President Biden on Home and Community-Based Services (3.22.2022)
• Comments to DOT on Air Travel by Persons Who Use Wheelchairs (3.21.2022)
• Group Letter to States on CDC Newborn Screening Grants (3.15.2022)
• Coalition Letter to Federal Partners on ABLE Act (3.14.2022)
• MDA FDA Comments on Real World Data and Evidence – Part 2 (03.09.2022)
• MDA Comments to FDA on Real World Data (2.28.2022)
• Coalition Letter on ARPA Expenditure Deadline Extension Request (2.25.2022)
• Healthy Futures Affordability Comments (02.22.2022)
• Coalition Letter to Appropriators (02.14.2022)
• Coalition Letter to CMS about Premiums (02.14.2022)
• Coalition Priorities Letter For Reconciliation (02.11.2022)
• Coalition Newborn Screening Letter to Congressional Leaders (02.04.2022)
• Group Comments on PREVENT Act (02.04.2022)
• Coalition Letter on EITC and CTC to Congressional Leaders (02.04.2022)
• Coalition Letter to President on Emergency Paid Leave (02.03.2022)
• Group Telehealth Letter to Congressional Leaders (01.31.2022)
• Coalition Letter to HHS on Short Term Limited Duration Plans (01.31.2022)
• Coalition HHS Comments on Notice of Benefits and Payment Parameters (01.27.2022)
• Group ACT for ALS Appropriations Letter (01.21.2022)
• Group DOT Lavatory Comments (01.15.2022)
• Group Newborn Screening Appropriations Letter (01.14.2022)

2021

• Group Statement on POTUS's ACT for ALS Signature (12.23.2021)
• Coalition Statement on SUNSET Rule (12.17.2021)
• MDA Statement on Senate Passage of ACT for ALS (12.16.2021)
• Group Statement on House Passage of ACT for ALS (12.08.2021)
• Coalition Statement on House Passage of Build Back Better Act (11.19.2021)
• Group Statement on HHS Good Guidance Rule (11.19.2021)
• MDA Statement on Full E&C ACT for ALS Markup (11.17.2021)
• DIVERSE Trials Act Sign-On Letter (11.15.2021)
• Group Letter on NCATS and NIH Appropriations (11.10.2021)
• Coalition Letter to Congressional Leaders on NBS Appropriations (11.8.2021)
• Coalition Comments on HHS Strategic Plan (11.5.2021)
• Coalition Statement on Paid Leave in Build Back Better House Bill (11.5.2021)
• MDA Statement on ACT for ALS Markup (11.4.2021)
• Updated: Coalition Letter to Senators Wyden and Crapo on Disability Employment Incentive Act (11.02.2021)
• ALS Groups Statement on ACT for ALS (11.1.2021)
• Governor Letters on Telehealth Flexibility (11.1.2021)
• Paid Leave Coalition Statement on Build Back Better Bill (10.29.2021)
• Coalition Letter to Senators Wyden and Crapo on Disability Employment Incentive Act (10.29.2021)
• Comments on PDUFA Reauthorization (10.28.2021)
• Coalition Letter to Secretary Becerra on Paid Family and Medical Leave (10.26.2021)
• Coalition Comments on Air Ambulances (10.18.2021)
• Paid Leave Letter to the White House, Congressional Leadership, and Senator Manchin (10.12.2021)
• Coalition Priorities on Build Back Better Package (10.12.2021)
• Coalition Letter on Supply Reimbursement Parity (10.05.2021)
• PDUFA Hearing Public Testimony (9.28.2021) 
• Coalition Letter to U.S. House and U.S. Senate on the Orphan Drug Program (9.21.2021)
• Coalition Letter to State Medicaid Directors (9.17.2021)
• Coalition Statement on Energy & Commerce Committee (9.17.2021)
• NCATS Support Letter (9.15.2021)
• Coalition Comments on Reconciliation Bill (9.10.2021)
• Coalition Comments on Surprise Medical Billing (9.7.2021)
• Coalition Letter to Congressional Leaders on Paid Medical Leave (8.23.2021)
• Coalition Letter on Advance Premium Tax Credits (8.3.2021)
• Coalition Principles on Paid Medical Leave (8.2.2021)
• Coalition Letter on Public Option Insurance Option (7.31.2021)
• AAPD NIST Public Comments on Voting Access (7.16.2021)
• Coalition Statement on No Surprises Act Rule (7.14.2021)
• Group Letter to U.S. House Leadership on ACT for ALS (7.13.2021)
• Coalition Comments to OMB on Advancing Equity and Support for Underserved Communities (7.6.2021)
• MDA Comments to NCART (6.30.2021)
• Amicus Brief Group Statement on Texas v. California Court Decision (6.17.2021)
• Group Statement on Texas v. California Court Decision (6.17.2021)
• Group Comments on No Surprises Act (6.9.2021)
• Group Statement on ACT for ALS bill (5.25.2021)
• Group Letter Urging CDC to Add LGMD Codes (5.10.2021)
• Coalition Statement on Next Health Coverage Legislative Package (5.6.2021)
• Coalition Letter to Congress about Consumer Assistance Program Funding (4.26.2021)
• Coalition Letter to Congressional Leaders and President Biden on Upcoming Health Care Legislation (4.23.2021)
• Group Letter on Maintenance of Effort Rule (4.6.2021)
• MDA Comments on Human Gene Therapy for Neurodegenerative Diseases (4.6.2021)
• Coalition Letter to House E&C Committee on Health Care Legislation (3.22.2021) 
• MDA Comments on NINDS Strategic Plan (3.15.2021)
• Letter to U.S. House and Senate about Newborn Screening Program Funding (3.8.2021)
• Letter to ACIP on Vaccinating Rare Disease Patients (2.26.2021)
• Letter to CDC on Vaccinating Rare Disease Patients (2.17.2021)
• Comments on DOT Strategic Plan (2.16.2021)
• Coalition Statement to Energy & Commerce Committee on COVID Package (2.11.2021)
• Coalition Statement to Ways & Means Committee on COVID Package (2.10.2021)
• Coalition Statement to Congress on Legislative Priorities (2.1.2021)
• Coalition Statement on COVID-19 Reconciliation Bill (2.1.2021)
• Coalition Statement on President Biden's Healthcare Executive Orders (1.29.2021)
• Coalition Statement on Tennessee Block Grant (1.8.2021)

2020

• Coalition Statement on IFC (12.21.2020)
• Coalition Statement on the No Surprises Act (12.16.2020)
• Letter to Localities about COVID-19 Vaccine Distribution (12.16.2020)
• Coalition Telehealth Letter to Congressional Leadership (12.9.2020)
• Coalition Letter to Congressional Leadership on Surprise Medical Bills (12.4.2020)
• LGMD ICD-10 Code Nomination and Community Letter (12.4.2020)
• Coalition Letter to President-Elect Biden (11.24.2020)
• Coalition Comments on American Airlines Weight Restrictions (11.6.2020)   
• MDA Comments to CDC Advisory Committee on Immunization Practice (10.30.2020)
• MDA, ALS Association, IAMALS Statement on new ACT for ALS (10.29.2020)
• Coalition 100 Days Agenda (10.13.2020)
• Coalition Press Release on Telehealth Principles (9.24.2020)
• MDA Comments to FDA on Statistical Considerations for Clinical Trials During COVID-19 (9.16.2020)
• Coalition Comments on Health and Human Services Good Guidance Practices (9.16.2020)
• ALS Community Statement on SSDI Bill (9.15.2020)
• Overall Coalition Principles on Telehealth (9.11.2020)
• Coalition Telehealth Principles Letter to CMS, Congressional Leaders, House Energy & Commerce Committee, House Ways & Means Committee, Senate Finance Committee, and Senate HELP Committee (9.11.2020)
• Letter to US House and Senate on Newborn Screening Program Appropriations (9.10.2020)
• Letter US House Leadership on ALS Disability Insurance Access Act (9.9.2020)
• Letter to Vice President Regarding COVID-19 Testing (9.3.2020)
• MDA Comments on PDUFA Reauthorization (8.23.2020)
• MDA Comments on Potential Regulatory Delays (8.17.2020)
• MDA Comments to FDA on Global Clinical Trials (7.31.2020)
• MDA Response to NINDS Rigor RFI (7.31.2020)
• Coalition Letter on Surprise Medical Billing (7.31.2020)
• Coalition Letter to Congression Leaders on 5th COVID-19 Package (7.28.2020)
• Coalition Letter on Current and Future Measures to Address Pandemics (6.30.2020)
• Letter and Press Statement on Telehealth Post-COVID-19 (6.29.2020)
• Coalition Statement on Patient Protection and Affordable Care Enhancement Act (6.29.2020)
• Coalition Statement on TSA Rules During COVID-19 (6.22.2020)
• MDA Statement on Act for ALS and PPA bills (6.18.2020)
• Coalition Statement on 1557 Regulations (6.15.2020)
• Coalition Statement on Airline Travel During COVID-19 (6.5.2020)
• MDA Statement on ALS Clinical Trial Design (5.26.2020)
• Coalition Letter Urging Lawmakers to Increase Support for the Medicaid Program (5.26.2020)
• Coalition Letter on Surprise Medical Bills to Congressional Leadership and President Trump (5.21.2020)
• Coalition Letter to the Office of Civil Rights on Emergency Triage Policies (5.20.2020)
• National Health Council Comments to CMS on Public Health Emergencies During COVID-19 (5.14.2020)
• Comments to the FDA on Clinical Trials During COVID-19 Pandemic (4.29.2020)
• Coalition Statement Supporting HR 6514 (4.24.2020)
• Patient Advocacy Letter Urging Administration Officials to Release Non-Discrimination COVID-19 Guidance (4.16.2020) 
• Patient and Community Group Letter to House and Senate Leadership Urging More Medical Research and CDC Funding During COVID-19 Pandemic (4.15.2020)
• Consortium Letter to Senate and House Subcommittees on Defense Appropriations (4.14.2020)
• Coaltion Letter to Congressional Leaders about Fourth COVID-19 Bill (4.14.2020)
• Group Letter to Congressional Leaders about Expanding the Paid Family and Medical Leave Act (4.9.2020)
• Coalition Letter to Congressional Leaders about Surprise Medical Billing in COVID-19 Legislation (4.8.2020)
• Letter to Congressional Leaders about Non-Invasive Ventilators (4.8.2020)
• Groups' Guidance on Anti-Discrimination COVID-19 Bulletin to States and Hospitals (4.3.2020)
• Coalition Statement to Administration Urging a Special ACA Enrollment Period (4.1.2020)
• Coalition Statement to Administration on Steps to Slow the Spread of COVID-19 (3.30.2020)
• Coalition Statement of the 10th Anniversary During the Affordable Care Act (3.23.2020)
• Charitable Organizations COVID-19 Relief Sign-On Letter (3.20.2020)
• Patient and Disability Group Statement on Medication Access in COVID-19 Stimulus (3.20.2020)
• Nonprofit groups on COVID-19 Stimulus (3.18.2020)
• Coalition Press Statement on Families First Coronavirus Response Act (3.16.2020)
• Coalition Letter to Senate Leadership on Families First Coronavirus Response Act (3.16.2020)
• Coalition Letter to CMS Administrator Seema Verma on Medicaid Block Grants (3.9.2020)
• Coalition Comments on HHS Notice of Benefit and Payment Parameters for 2021 (3.2.2020)
• Coalition Principles on Surprise Medical Billing (3.2.2020)
• Coalition Comments to DOT on Airplane Lavatories (3.2.2020)
• Coalition Statement on Consumer Protections Against Surprise Medical Bills Act of 2020 markup (2.12.2020)
• Coalition Statement on Ban Surprise Billing Act markup (2.11.2020)
• MDA Comments on the Conditional Approval Act (S.3133) (2.3.2020)
• Comments on Medicaid Fiscal Accountability rule (1.31.2020)​
• Coalition Statement on Medicaid Block Grant Guidance (1.30.2020)

2019

• Coalition Statement on Texas vs. US Appellate Court Ruling (12.19.19)
• Letter to HHS Secretary Alex Azar on extending the charter of the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) (12.19.19)
• Statement applauding Bipartisan, Bicameral Deal Protecting Patients and Consumers from Surprise Medical Bills (12.12.2019)
• Letter to House and Senate urging the co-sponsorship of the Medical Expense Savings Act (12.4.2019).
• Letter to House Leadership in support of the Access to Genetic Counselor Services Act of 2019 (11.20.2019).
• Letter to House and Senate in support of PCORI (11.04.2019).
• Comments on Access Board Advisory Guidelines for Onboard Wheelchairs (10.21.2019). 
• Letter to ICER on Value Assessment Framework (10.18.2019)
• Letter to Leadership on Suprise Medical Billing (10.2.2019).
• Comments on Rare Pediatric Disease Priority Review Vouchers (9.30.2019).
• Letter to ICER on Value Assessment Framework (09.06.2019) 
• Comments on FDA's Draft Guidance on Clinical Trial Eligibility (08.06.2019)
• Letter to the Honorable Seema Verma in support of Medicaid (07.18.2019)
• Request for Comment on the consumer inflation measures produced by the federal statistical agencies (06.21.2019)
• Letter to ICER on value assessment framework (06.10.2019)
• Letter to Senator Susan Collins and Senator Maria Cantwell in Support of S.110 (06.06.2019)
• Letter to Representative Marchant and Representative Porter in support of H.R. 2073 (06.06.2019)
• Letter to Representative Kathy Castor in support of H.R. 1010 (05.15.2019).
• Letter to Representative Lisa Blunt Rochester in support of H.R. 987 (05.15.2019)
• Letter to Representative Pallone and Representative Walden on health coverage accessibility​ (05.08.2019).
• Letter to Representative Kuster in support of  H.R. 986 (05.06.2019)
• Statement for the record in support of H.R. 1010​ (04.08.2019).
• Letter on Patient Protection and Affordable Care Act (02.19.2019)

2018

• Letter to Secretary Azar on section 1332 (12.18.2018). 
• Comments on states applying for waivers under Section 1332 of the Affordable Care Act (12.18.2018).
• Comments on the recent Ruling in Texas v. US (12.17.2018).
• Comments on the DHS notice of proposed rulemaking on inadmissibility on public grounds charges (12.10.2018).
• Comment titled, "CMS Guidance Puts Millions of Americans with Pre-Existing Conditions at Risk" (10.24.2018)
• Letter to Senator Thom Tillis urging Senate to reconsider approach to S.3388 (09.19.2018)
• Letter to Representative Kevin Brady asking that the medical expense deduction be made permanent (09.13.2018)
• Statement regarding S.3388, the Ensuring Coverage for Patients with Pre-Existing Conditions Act (09.04.2018)
• Letter to Chair of Florida Genetics and Newborn Screening Advisory Council (08.23.2018)
• Statement on rule released by the U.S. Department of labor that would expand the use of association health plans (06.19.2018)